UNASSIGNED: 2040 Background: @entity1 with recurrent or progressive @entity1653 who have exhausted surgical and radiation options have limited remaining treatment choices. @entity1943 receptors are expressed in nearly 90% of @entity1653 , and @entity1943 inhibits @entity1653 growth in vitro. The @entity1943 analog @entity2390 had promising results in a pilot clinical study. Pasireotide @entity8800 is a long-acting @entity1943 analog that has higher binding affinity for most @entity1943 receptor subtypes than @entity2390 . METHODS: This is an open label, single arm phase II trial of monthly pasireotide @entity8800 60 mg intramuscularly in @entity1 with recurrent or progressive @entity1653 . Treatment cycles are 28 days. Treatment continues until progressive disease or unacceptable @entity137 . Restaging MRIs are performed every 3 cycles and response is assessed using Macdonald criteria. @entity2390 scans are performed in all @entity1 at baseline. RESULTS: Twenty-six @entity1 have been accrued, 17 (65%) of whom have atypical/ @entity5 , median age 56 (range 36-74), 11 @entity1 (42%), median KPS 85 (range 60-100), and 22 (85%) with previous radiation therapy. Twenty-two @entity5 (85%) show at least intermediate @entity2390 uptake. There are no radiographic responses. Of 22 evaluable @entity1 , 16 (73%) achieved stable disease. Median PFS overall is 20 weeks (95% CI: 9-21) and PFS6 29% ( @entity1653 - median PFS 27 weeks [95% CI: 8-not yet reached], PFS6 50%; atypical/ @entity5 - median PFS 16 weeks [95% CI: 8-20], PFS6 20%). @entity137 has been mild except for grade 3 @entity4854 in 5 (19%) @entity1 , grade 4 @entity4854 in 1 (4%) @entity1 , and grade 3 lipase in 2 (8%) @entity1 . CONCLUSIONS: Pasireotide @entity8800 is a well-tolerated @entity1943 analog that is under investigation for heavily pre-treated, recurrent @entity1653 . Updated results will be presented at the meeting.

Phase II study of monthly pasireotide XXXX (SOM230C) for recurrent or progressive @entity1653 .

@entity1 :: ('9606', 'Species') :: ['men', 'participants', 'Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant meningiomas', 'tumors'] @entity8800 :: ('5792', 'Gene') :: ['LAR'] @entity1653 :: ('MESH:D008579', 'Disease') :: ['intracranial meningioma', 'benign meningiomas', 'meningioma', 'meningiomas'] @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide', 'Octreotide'] @entity1943 :: ('MESH:D013004', 'Chemical') :: ['somatostatin', 'Somatostatin'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']
@entity8800 :: (5792,Gene) :: ['LAR']
